NCT06469138 - A Study to Investigate 14C-bemcentinib in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

September 23, 2022

Study Completion Date

September 23, 2022

Conditions

Non-Small Cell Lung CancerMetastatic MelanomaAcute Myeloid LeukemiaMyelodysplastic SyndromesMetastatic Pancreatic CancerGlioblastomaMalignant MesotheliomaCOVID-19

Interventions

DRUG

Bemcentinib

Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.

Trial Locations (1)

LS2 9LH

Labcorp Clinical Research Unit Ltd., Leeds